Certis can provide a variety of endpoints, including tumor volume calculations over time compare to control group, growth curves, PK/PD sampling and analysis, biomarker identification, immune cell characterization by flow cytometry, toxicity, ADME, overall survival, and disease-free survival (Kaplan Meier Curves), necropsy analysis of metastasis, cell population characterization, phenotypic analysis, histological analysis and enzyme-linked immunoassay (ELISA). Common pharmacological endpoint analysis includes Homogeneous Time-Resolved Fluorescence (HTRF), Meso Scale Discovery (MSD®), spectral flow cytometry for analyzing cell subpopulations in blood (on study) and/or post-takedown in other tissues.